Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP 102
- Development stage
- Phase 2
- Lead developer
- Celltrion
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Intrathecal
01
Overview
ABP 102 refers to two distinct therapeutic candidates in development by different companies. The first is a bispecific T-cell engager (BiTE) developed by Abpro and licensed to Celltrion for the treatment of HER2-positive cancers, including breast, gastric, and pancreatic cancers. Developed using the MultiMab platform, it is designed to simultaneously bind HER2 on tumor cells and CD3 on T-cells, thereby facilitating the targeted destruction of malignant cells. The second is an AAV-based gene therapy originally developed by Apic Bio and licensed to uniQure (renamed AMT-162) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). This therapy utilizes an adeno-associated virus (AAV) vector to deliver a microRNA payload designed to silence the expression of mutant SOD1, which is a key driver of disease progression in this subset of ALS patients.
- Other names
- AMT-162AMT162AMT 162
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)Misfolded SOD1
Beyond the preview
Go deeper on ABP 102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP 102.